No products in the cart.
Pre-made Rovalpituzumab benchmark antibody ( Whole mAb ADC, anti-DLL3 therapeutic antibody, Anti-SCDO1 Antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-497
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Rovalpituzumab biosimilar, Whole mAb ADC, Anti-DLL3 Antibody: Anti-SCDO1 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Rovalpituzumab tesirine (Rova-T) is an experimental antibody-drug conjugate targeting the protein DLL3 on tumor cells. It was originally developed by Stemcentrx and was purchased by AbbVie.[3] It was tested for use in small-cell lung cancer, but development was terminated after unsuccessful phase III trial.
| Products Name (INN Index) | Pre-Made Rovalpituzumab biosimilar, Whole mAb ADC, Anti-DLL3 Antibody: Anti-SCDO1 therapeutic antibody |
|---|---|
| INN Name | Rovalpituzumab |
| Target | DLL3 |
| Format | Whole mAb ADC |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2015 |
| Year Recommended | 2016 |
| Companies | Bristol-Myers Squibb,Stemcentrx |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Small cell lung cancer,Solid tumours |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | DLL3 |
| Package |
Previous slide
Next slide
